Advanced search
Publication Cover
Emerging Microbes & Infections Volume 13, 2024 - Issue 1
Submit an article Journal homepage
752
Views
0
CrossRef citations to date
0
Altmetric
Emerging and Re-Emerging Coronaviruses

Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1

Sijie Yanga Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People’s Republic of China;b Changping Laboratory, Beijing, People’s Republic of China;c Peking-Tsinghua Center for Life Sciences, Tsinghua University, Beijing, People’s Republic of ChinaView further author information
,
Yuanling Yub Changping Laboratory, Beijing, People’s Republic of ChinaView further author information
,
Fanchong Jiana Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People’s Republic of China;b Changping Laboratory, Beijing, People’s Republic of China;d College of Chemistry and Molecular Engineering Peking University, Beijing, People’s Republic of ChinaView further author information
,
Ayijiang Yisimayia Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People’s Republic of China;b Changping Laboratory, Beijing, People’s Republic of China;e School of Life Sciences, Peking University, Beijing, People’s Republic of ChinaView further author information
,
Weiliang Songa Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People’s Republic of China;b Changping Laboratory, Beijing, People’s Republic of China;e School of Life Sciences, Peking University, Beijing, People’s Republic of ChinaView further author information
,
Jingyi Liua Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People’s Republic of China;b Changping Laboratory, Beijing, People’s Republic of China;f College of Future Technology Peking University, Beijing, People’s Republic of ChinaView further author information
,
Peng Wangb Changping Laboratory, Beijing, People’s Republic of ChinaView further author information
,
Yanli Xug Beijing Ditan Hospital Capital Medical University, Beijing, People’s Republic of ChinaView further author information
,
Jing Wangb Changping Laboratory, Beijing, People’s Republic of ChinaView further author information
,
Xiao Niua Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People’s Republic of China;b Changping Laboratory, Beijing, People’s Republic of China;d College of Chemistry and Molecular Engineering Peking University, Beijing, People’s Republic of ChinaView further author information
,
Lingling Yub Changping Laboratory, Beijing, People’s Republic of ChinaView further author information
,
Yao Wangb Changping Laboratory, Beijing, People’s Republic of ChinaView further author information
,
Fei Shaob Changping Laboratory, Beijing, People’s Republic of ChinaView further author information
,
Ronghua Jing Beijing Ditan Hospital Capital Medical University, Beijing, People’s Republic of ChinaView further author information
,
Youchun Wangb Changping Laboratory, Beijing, People’s Republic of China;h Institute of Medical Biology Chinese Academy of Medical Science & Peking Union Medical College, Kunming, People’s Republic of ChinaView further author information
&
Yunlong Caoa Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People’s Republic of China;b Changping Laboratory, Beijing, People’s Republic of China;e School of Life Sciences, Peking University, Beijing, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Article: 2343909 | Received 10 Mar 2024, Accepted 11 Apr 2024, Published online: 02 May 2024

References

  • Wang X, Jiang S, Ma W, et al. Robust neutralization of SARS-CoV-2 variants including JN.1 and BA.2.87.1 by trivalent XBB vaccine-induced antibodies. bioRxiv. 2024. doi:10.1101/2024.02.16.580615
  • Zhang L, Dopfer-Jablonka A, Nehlmeier I, et al. Virological traits of the SARS-CoV-2 BA.2.87.1 lineage. bioRxiv; 2024.
  • Cao Y, Song W, Wang L, et al. Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75. Cell Host Microbe. 2022;30:1527–1539.e5. doi:10.1016/j.chom.2022.09.018
  • Yang S, Yu Y, Xu Y, et al. Fast evolution of SARS-CoV-2 BA.2·86 to JN.1 under heavy immune pressure. Lancet Infect Dis. 2023;24:e70–e72. doi:10.1016/S1473-3099(23)00744-2
  • Yang S, Yu Y, Jian F, et al. Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86. Lancet Infect Dis. 2023;23:e457–e459. doi:10.1016/S1473-3099(23)00573-X
  • Yisimayi A, Song W, Wang J, et al. Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting. Nature. 2024;625:148–156. doi:10.1038/s41586-023-06753-7
  • Jian F, Feng L, Yang S, et al. Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455–456 synergistically enhances antibody evasion and ACE2 binding. Wan X-F, editor. PLoS Pathog. 2023;19:e1011868. doi:10.1371/journal.ppat.1011868
  • Jian F, Yu Y, Song W, et al. Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants. Lancet Infect Dis. 2022;22:1535–1537. doi:10.1016/S1473-3099(22)00642-9
  • Cao Y, Jian F, Zhang Z, et al. Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents. Cell Rep. 2022;41:111845. doi:10.1016/j.celrep.2022.111845
  • Copin R, Baum A, Wloga E, et al. The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies. Cell. 2021;184:3949–3961.e11. doi:10.1016/j.cell.2021.06.002
  • Zost SJ, Gilchuk P, Case JB, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020;584:443–449. doi:10.1038/s41586-020-2548-6
  • Xu S, Wang Y, Wang Y, et al. Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein. Emerg Microbes Infect. 2022;11:351–367. doi:10.1080/22221751.2021.2024455
  • Westendorf K, Žentelis S, Wang L, et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep. 2022;39:110812. doi:10.1016/j.celrep.2022.110812
  • Nutalai R, Zhou D, Tuekprakhon A, et al. Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. Cell. 2022;185:2116–2131.e18. doi:10.1016/j.cell.2022.05.014
  • Wang Q, et al. SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1. bioRxiv; 2024.
  • Li P, et al. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity and cell-cell fusion. bioRxiv; 2024.
  • Lasrado N, Rössler A, Rowe M, et al. Neutralization of SARS-CoV-2 omicron subvariant BA.2.87.1. Vaccine. 2024;42:2117–2121. doi:10.1016/j.vaccine.2024.03.007
  • Sheward DJ, Marking U, Bladh O, et al. Neutralisation sensitivity of the SARS-CoV-2 BA. 2.87. 1 variant. bioRxiv; 2024.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.